Recombinant Human Tyrosine-protein kinase JAK1(JAK1),partial

Code CSB-YP011930HU
Size US$1916
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.

Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity Greater than 90% as determined by SDS-PAGE.
Target Names JAK1
Uniprot No. P23458
Research Area Cancer
Alternative Names JAK 1; JAK 1A; JAK 1B; JAK-1; JAK1; JAK1_HUMAN; JAK1A; JAK1B; Janus kinase 1 (a protein tyrosine kinase); Janus kinase 1; JTK3; Tyrosine protein kinase JAK 1; Tyrosine protein kinase JAK1; Tyrosine-protein kinase JAK1
Species Homo sapiens (Human)
Source Yeast
Expression Region 850-1154aa
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight 36.9kDa
Protein Length Partial
Tag Info N-terminal 6xHis-tagged
Form Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
and FAQs
Protein FAQs
Storage Condition Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA Please contact us to get it.

Target Data

Function Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway
Gene References into Functions
  1. Low-dose radiation decreases tumor progression via the inhibition of the JAK1/STAT3 signaling axis in breast cancer cell lines and in a mouse xenograft model. PMID: 28240233
  2. Case Report: breast implant-associated anaplastic large cell lymphoma with dual JAK1/STAT3 mutations. PMID: 29637270
  3. A small drug acting as a JAK1/2 inhibitor may also counteract the repressing effects of IL-6. PMID: 29162613
  4. These findings clarify JAK1 signalling mechanisms and demonstrate a critical function of JAK1 in protection against mycobacterial infection and possibly the immunological surveillance of cancer. PMID: 28008925
  5. In the Title. PMID: 27554814
  6. Study concluded that JAK1 plays a role in the pathogenesis of both vitiligo and psoriasis based on its upregulated level before treatment and downregulated level after treatment. PMID: 29127481
  7. High JAK1 expression is associated with metastasis of pancreatic ductal adenocarcinoma. PMID: 28677798
  8. IL6 family cytokine oncostatin-M (OSM) induced a switch to the EMT phenotype and protected cells from targeted drug-induced apoptosis in OSM receptors (OSMRs)/JAK1/STAT3-dependent manner PMID: 28729401
  9. Amorfrutin A also inhibited activation of the upstream kinases Janus-activated kinase 1 (JAK1), JAK2 and Src signaling pathways. PMID: 28879797
  10. Jak1 is required for the survival of anaplastic large cell lymphoma.Jak1 mutations in anaplastic large cell lymphoma. PMID: 28356514
  11. The good consonance between the docking results and CoMFA/CoMSIA contour maps provides helpful clues about the reasonable modification of molecules in order to design more efficient JAK 1 inhibitors. The developed models are expected to provide some directives for further synthesis of highly effective JAK 1 inhibitors. PMID: 28537140
  12. Here we report a molecular mechanism by which JAK1 contributes to the malignant phenotype of activated B-cell diffuse large B-cell lymphoma (ABC DLBCL). Epigenetic regulation by JAK1 plays a prominent role in the gene expression program of ABC DLBCL cells by phosphorylating chromatin on H3Y41. The chromatin of nearly 3,000 genes had JAK1-dependent H3Y41 phosphorylation marks and required JAK1 for their expression. PMID: 27799566
  13. miR-30e has a critical role in the suppression of hepatocellular carcinoma (HCC) and presents a novel mechanism of miRNA-mediated JAK1 expression in cancer cells that might be a good prognostic marker for survival of HCC patients. PMID: 28560434
  14. We demonstrate that impaired recruitment of CD11b(+) myeloid cells with a JAK1/2 inhibitor inhibits glioma progression in vivo and prolongs survival in a murine glioma model. PMID: 28039266
  15. Whole-exome sequencing on patients with acute lymphoblastic leukemia (ALL) and discovered a somatic JAK1 S646P mutation. Functional studies demonstrated that only JAK1 S646P mutation could activate multiple signaling pathways, drive cytokine-independent cell growth, and promote proliferation of malignant cells in nude mice. PMID: 28410228
  16. we have identified acquired activating mutations in JAK1 and STAT3 in two cases of effusion-limited BIA-ALCL and identified a possible contribution to disease development from a germline JAK3 variant. PMID: 27198716
  17. JAK1 mutations are highly frequent in microsatellite unstable endometrial cancer, not associated with survival, but are associated with impaired upregulation of LMP7 and HLA class I and may therefore facilitate immune escape PMID: 27213585
  18. We found that a significant higher gastric cancer risk was associated with IL-6 rs2069837G variant genotypes and JAK1 rs2230587A variant genotypes PMID: 27049718
  19. 6-Hydroxy-3-O-methyl-kaempferol 6-O-glucopyranoside potentiated the inhibitory effect of IFN-alpha on hepatocellular carcinoma cell proliferation through activation of the JAK/STAT signaling pathway by inhibiting SOCS3 expression. PMID: 29031523
  20. JAK1 frameshifts are loss of function alterations that represent a potential pan-cancer adaptation to immune responses against tumors with microsatellite instability PMID: 29121062
  21. Study provides evidence that JAK1/2 loss-of-function mutations are a genetic mechanism of lack of reactive PD-L1 expression and response to interferon gamma, leading to primary resistance to PD-1 blockade therapy. PMID: 27903500
  22. This study demonstrates that the nuclear import of JAK1 is essential for the optimal fitness of ABC DLBCL cells. PMID: 28031410
  23. JAK1 rs11576173 and rs1497056 genotypes were significantly related to severe necroinflammatory activity (NIA) grade of chronic hepatitis C patients. PMID: 28704535
  24. Multiple myeloma cells over express JAK1/2 and suggest combined chemotherapy with ruxolitinib, bortezomib and lenalidomide to inhibit JAK/STAT pathway. PMID: 28645562
  25. Mechanistic investigations reveal that AJUBA specifically binds the FERM domain of JAK1 to dissociate JAK1 from the IFNgamma recepter, resulting in an inhibition of STAT1 phosporylation and concomitantly its nuclear translocation. Clinically, the level of AJUBA in CRC specimens is negatively correlated with the levels of IFIT2 and pSTAT1 PMID: 27893714
  26. Multilevel genomic analyses of microsatellite instability+ colorectal cancer revealed molecular heterogeneity with clinical relevance, including tumor immunogenicity and a favorable patient outcome associated with JAK1 mutations and the transcriptomic subgroup CMS1 PMID: 28539123
  27. a causal relationship between MLH1-deficiency and incidence of oncogenic point mutations in tyrosine kinases driving cell transformation and acquired resistance to kinase-targeted cancer therapies, is reported. PMID: 27436342
  28. Data show that moringin (GMG-ITC) had a limited inhibitory effect on IFNalpha-induced STAT1 and STAT2 activity, indicating differentially targeting JAK/STAT signaling pathways. PMID: 27304884
  29. our studies highlight Jak1 as the first identified substrate for USP6, and they offer a mechanistic rationale for the clinical investigation of Jak and STAT3 inhibitors as therapeutics for the treatment of bone and soft tissue tumors along with other neoplasms driven by USP6 overexpression PMID: 27440725
  30. In this structure, the receptor peptide forms an 85-A-long extended chain, in which both the previously identified box1 and box2 regions bind simultaneously to the FERM and SH2-like domains of JAK1. PMID: 27725180
  31. Results reveal the structure of box1 from class II cytokine receptors IFNLR1 and IL10RA bound to the FERM-SH2 domain of human JAK1, identifying a consensus motif for JAK1 interaction. PMID: 27133025
  32. study demonstrated that miR-9 could inhibit activation of the NLRP3 inflammasome and attenuate atherosclerosis-related inflammation, likely through the JAK1/STAT1 signaling pathway. Therefore, miR-9 may serve as a potential therapeutic target for atherosclerosis. PMID: 28334721
  33. miR-340 suppressed HCC cell proliferation and invasion by regulating the JAK1/STAT3 pathway PMID: 27998770
  34. this study identifies a psoriasis-protective JAK1 haplotype in the Korean population PMID: 27774581
  35. Data show that tight junction protein 1 (TJP1) suppressed expression of the catalytically proteasome subunits LMP7 and LMP2, decreased proteasome activity, and enhanced proteasome inhibitor sensitivity in vitro and in vivo through suppression of EGFR/JAK1/STAT3 signaling. PMID: 27132469
  36. EGFR Del 19 may promote Fn14 and JAK1/STAT1 expression in NSCLC. PMID: 27350337
  37. Piperlongumine reduced the phosphorylation of Janus kinase (JAK)1, JAK2 and signal transducer and activator of transcription (STAT)3 in a concentrationdependent manner PMID: 27053336
  38. JAK1 rs310241 C-related genotype and allele are involved in AR susceptibility, making them potentially useful genetic biomarkers for allergic rhinitis susceptibility in the Chinese Han population. PMID: 27007833
  39. Data show that astaxanthin functions as a potent inhibitor of A549 lung cancer cell growth by targeting Janus kinase 1 a(JAK1)/STAT3 transcription factor (STAT3) signaling pathway. PMID: 27371847
  40. Genetic Variation in the JAK1 gene is associated with distal Colonic Disease, Stricturing Disease Behavior. PMID: 26937622
  41. Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma. PMID: 26701727
  42. Foot-and-mouth disease virus VP3 interacted with JAK1/2, degraded JAK1, and inhibited the tyrosine phosphorylation, dimerization and nuclear accumulation of STAT1. PMID: 26901336
  43. Data suggest that targeting both TGF-beta and Janus kinase 1 (JAK1) signaling could be explored therapeutically in pancreatic ductal adenocarcinomas (PDACs) patients whose cancers exhibit an angiogenesis gene signature. PMID: 26586478
  44. When association tests were applied to data from the Diabetes Heart Study, it found exome variants of POMGNT1 and JAK1 genes were associated with type 2 diabetes. PMID: 26783077
  45. Studies indicate that Janus kinase 1 (JAK1) inhibition leads to depression in inflammatory cytokine expression associated with MF-related constitutional symptoms. PMID: 25586607
  46. Mutations leading to constitutive active gp130/JAK1/STAT3 pathway. PMID: 26188635
  47. Increased expression of SgK223 occurs in PDAC, and overexpression of SgK223 in pancreatic ductal epithelial cells promotes acquisition of a migratory and invasive phenotype through enhanced JAK1/Stat3 signaling PMID: 26215634
  48. Data show that IFN-lambda induced a faster but shorter expression of suppressor of cytokine signaling 1 (SOCS1) which inhibited Janus kinase/signal transducer and activator of transcription (Jak/STAT) pathway and phosphorylation. PMID: 26193702
  49. Shp-2 contributes to the control of respiratory syncytial virus replication and progeny production in pulmonary alveolar epithelial cells by interfering with IFN-alpha-induced Jak/Stat1 pathway activation PMID: 26119280
  50. Data show that JAK/STAT signaling inhibition is potentiated by Bcl-xL (B-cell lymphoma-extra large) blockade in interleukin 2 (IL-2) dependent adult T-cell leukemia cells. PMID: 26396258
  51. Genetic variants of the genes JAK1 and the TNFAIP3 were not associated with Behcet's disease in a Spanish population. PMID: 26005883
  52. Data indicate direct effects of sorafenib on the Janus kinase JAK1-transcription factors STAT3/5 signaling pathway in immune cells. PMID: 26238487
  53. Expression analysis revealed upregulation of IL6 and CD126 and GP130 in ALDH(hi) endometrial cancer ... targeted inhibition of the IL6 receptor and its downstream effectors JAK1 and STAT3 reduced tumor cell growth. PMID: 26130650
  54. -1 promotes IFN-alpha-induced autophagy via the JAK1-STAT1 signaling. PMID: 25959715
  55. Jak1/Stat3 may be beneficial for the treatment of H. pylori-induced gastric inflammation, since the activation of NF-kappaB is inhibited and inflammatory cytokine expression is suppressed. PMID: 25837197
  56. weak RELA-activation signals (CD40L, LPS) depended on IFN-gamma induced STAT1/IRF1/IRF8 co-signalling, which was completely blocked by JAK inhibitors as reported before PMID: 25931145
  57. JAK1, JAK2, and STAT1 are indispensable for the enhancement of prostaglandins production by follicular dendritic cell-like cells in response to IFN-gamma stimulation. PMID: 25818476
  58. Data show that IL-27 on IFN-gamma mediated autophagy perpetuates by simultaneous induction of kinases mTOR via JAK/PI3 K/Akt cascade and increment in myeloid cell leukemia sequence 1 (Mcl-1) level through PI3 K pathway. PMID: 25194337
  59. HCV infection upregulates miR-373 expression and impairs the JAK/STAT signaling pathway. PMID: 25589644
  60. Zn deficiency enhances the acute phase response and particularly the JAK-STAT3 pathway, resulting in increased serum amyloid A production. PMID: 24732911
  61. IL-10/Janus kinase/STAT3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndrome. PMID: 25174872
  62. This study demonstrates that EV71 inhibits the cellular type I IFN antiviral pathway by downregulating JAK1, while the expression of IFNAR1 does not significantly alter in EV71-infected cells. PMID: 24905060
  63. Activation of the Janus kinase/signal transducer and activator of transcription pathway in multiple myeloma is not related to point mutations in kinase and pseudokinase domains of JAK1. PMID: 23885837
  64. In cellular assays, SAR-20347 dose dependently (1 nM-10 muM) inhibited JAK1- and/or TYK2-dependent signaling from the IL-12/IL-23, IL-22, and IFN-alpha receptors. PMID: 25156366
  65. Knocking down of JAK2 and JAK1 inhibited proliferation of Jak2-positive/Jak1-negative H82 cells and Jak1-positive/Jak2-negative GLC4 cells, respectively PMID: 24158701
  66. These data indicate that JAK pseudokinases are autoinhibitory domains that hold the kinase domain inactive until receptor dimerization stimulates transition to an active state. PMID: 24843152
  67. These findings identify recurrent JAK1 truncating mutations that could contribute to tumor immune evasion in gynecologic cancers, especially in endometrial cancer. PMID: 24154688
  68. T-cell prolymphocytic leukemia is associated with a high rate of JAK1/3 mutations. PMID: 24048415
  69. different domains in SOCS5 contribute to two distinct mechanisms for regulation of cytokine and growth factor signaling with JAK1 and SHC-1 PMID: 23990909
  70. our findings suggest a novel strategy of using aspirin to overcome tumor resistance and enhance the effectiveness of IFN-alpha in HCC treatment through activating STAT1 gene, and have potential implications for improving future IFN-alpha protein and gene therapy. PMID: 23703473
  71. Data indicate that CRLF1 serves its protective role by a cell autonomous mechanism that is independent of the gp130/JAK signaling pathway. PMID: 23818941
  72. Data indicate that the anti-tumor effects of guggulsterone (GS) possibly involve multiple networks including inhibition of FAK, Src, and Jak/STAT signaling. PMID: 23920124
  73. In a cohort of 84 patients, study found 4 novel SNPs in patients with complete remission; results have shown that JAK1 mutation is rare in newly diagnosed APL patients, suggesting that these mutations in were unlikely to be involved in its pathogenesis PMID: 23860541
  74. Data indicate that ruxolitinib effectively inhibited JAK/STAT signalling in hepatocellular carcinoma (HCC) cells with a significant reduction in the expression of JAK downstream targets pSTAT1 and pSTAT3. PMID: 23941832
  75. Studies indicate that JAK/STAT pathway as a common underlying biologic abnormality in myeloproliferative neoplasms (MPN), and Ruxolitinib, a JAK1 and JAK2 inhibitor has recently been approved for the treatment. PMID: 23406773
  76. Genetic variants in the JAK1 gene confer higher risk of Behcet's disease with ocular involvement in Han Chinese. PMID: 23674219
  77. Progesterone (5 mum) leads to phosphorylation of JAK1, JAK2 and STAT1 in a time-dependent manner in sperm. PMID: 22748021
  78. Single nucleotide polymorphisms in Jak1 is associated with non-Hodgkin lymphoma. PMID: 23768868
  79. These results suggest that JAK1 genetic polymorphisms, but not JAK2 and STAT3, are associated with the susceptibility to Vogt-Koyanagi-Harada (VKH) syndrome. PMID: 23611997
  80. ubiquitin ligase TRAF6 negatively regulates the JAK-STAT signaling pathway by binding to STAT3 and mediating its ubiquitination PMID: 23185365
  81. In systemic lupus erythematosus but not in healthy control leukocytes, Jak1 and STAT2 were constitutively phosphorylated, even in the absence of disease activity. PMID: 22859983
  82. SNPs rs4244165 and rs17127024 in JAK1 were associated with outcomes of HBV infection, but not with response to IFNalpha therapy. PMID: 22901011
  83. vSOCS inhibits IFN-alpha-induced Stat1/Stat3 signaling. PMID: 22844427
  84. Janus kinase A is involved in the activation of STAT6 induced by IL-13 in bronchial smooth muscle cells. PMID: 22661199
  85. Gene silencing of two members of the JAK family, JAK1 and JAK2, increased the susceptibility of a variety of tumor cell types to natural killer-mediated lysis PMID: 22684105
  86. Upregulated JAG1 enhances cell proliferation in adrenocortical carcinoma. PMID: 22427350
  87. JAK1 and STAT6 may be universal mediators of IL-4 in the suppression of prostaglandin production in human follicular denritic cells. PMID: 22406175
  88. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia. PMID: 22368272
  89. Increased Phospho Jak1 is associated with progression of esophageal squamous cell carcinoma. PMID: 22301404
  90. Data show that that IL-4 signals through the Jak1, 2/Stat6 pathway in keratinocytes to stimulate CCL26 expression and this may provide an explanation for the pathogenesis of atopic dermatitis (AD). PMID: 22226123
  91. a new biological activity for CUEDC2 as the regulator of JAK1/STAT3 signaling and the mechanism by which SOCS3 has been linked to suppression of the JAK/STAT pathway PMID: 22084247
  92. JAK-1 rs2780895 C-related genotype and allele are associated with higher susceptibility to asthma. JAK-1 rs10789166, rs4916008, rs2780885, rs17127114, and rs3806277 single-nucleotide polymorphisms are not associated with asthma development. PMID: 21827323
  93. activated during human sperm capacitation PMID: 21880948
  94. in T-cell acute lymphoblastic leukemia, PHF6 mutations are a recurrent genetic abnormality associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214. PMID: 21880637
  95. infection of airway epithelial cells with hMPV decreased cellular level of Janus tyrosine kinase (Jak1) and tyrosine kinase 2 (Tyk2) PMID: 21949722
  96. Down-regulation of JAK1 by RNA interference inhibits growth of the lung cancer cell line A549 and interferes with the PI3K/mTOR pathway. PMID: 21861134
  97. Mutations in JAK1 were found in one (7%) myeloid leukemia-Down Syndrome patient (D625R) and in one (3%) Down Syndrome-acute lymphoblastic leukemia patient (V651 M). PMID: 21537335
  98. show that cytokine signaling through the receptor subunit GP130-IL6ST and the kinase JAK1 generates actomyosin contractility through Rho-kinase dependent signaling PMID: 21840487
  99. Author's results suggest that JAK1 rather than EGFR or Src signaling is responsible for STAT3 activation in lung cancer cells. PMID: 21216930
  100. Activating mutations in JAK1 occur in approx 10% of T-ALL. Leukemic transformation in cells expressing activating JAK1 mutations is modulated by PTPN2. Down-regulation of PTPN2 reduces lymphoid cells sensitivity to JAK inhibition. PMID: 21551237

Show More

Hide All

Subcellular Location Endomembrane system, Peripheral membrane protein
Protein Families Protein kinase superfamily, Tyr protein kinase family, JAK subfamily
Tissue Specificity Expressed at higher levels in primary colon tumors than in normal colon tissue. The expression level in metastatic colon tumors is comparable to the expression level in normal colon tissue.
Database Links

HGNC: 6190

OMIM: 147795

KEGG: hsa:3716

STRING: 9606.ENSP00000343204

UniGene: Hs.207538

Most popular with customers


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1